Anti-CDH17 antibody-drug conjugates and uses thereof
WO2026124417A1PCT designated stage Publication Date: 2026-06-18LEPU BIOPHARMA CO LTD
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- LEPU BIOPHARMA CO LTD
- Filing Date
- 2025-12-08
- Publication Date
- 2026-06-18
AI Technical Summary
Technical Problem
Existing antibody-drug conjugates (ADCs) face challenges in achieving enduring efficacy and reducing toxicity, particularly for CDH17-positive gastrointestinal cancers, due to issues with payload stability and non-specific toxicity.
Method used
Development of an anti-CDH17 ADC (ADC-1) with a stable exatecan payload and a Fc-disabled design, utilizing a metal-free click reaction for conjugation, which enhances cytotoxicity and reduces non-specific toxicity.
Benefits of technology
ADC-1 exhibits improved therapeutic window with lower minimum efficacious dose and maximum tolerable dose, showing enhanced cytotoxicity against CDH17-positive tumors and reduced toxicity, particularly in colorectal and pancreatic cancers.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2025140793-FTAPPB-I100001 
Figure PCTCN2025140793-FTAPPB-I100002 
Figure PCTCN2025140793-FTAPPB-I100003
Abstract
Antibody drug conjugates having highly selective specificity to the human CDH17 protein are identified, which may be useful for treating cancer. The antibody drug conjugates can exhibit efficient in vitro and in vivo tumor cell killing.
Need to check novelty before this filing date? Find Prior Art